Alector Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 241

Employees

  • Stock Symbol
  • ALEC

Stock Symbol

  • Share Price
  • $5.75
  • (As of Friday Closing)

Alector General Information

Description

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Contact Information

Website
www.alector.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 151 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 151 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (415)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alector Stock Performance

As of 08-Nov-2024, Alector’s stock price is $5.75. Its current market cap is $563M with 97.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.75 $5.64 $3.66 - $8.90 $563M 97.9M 527K -$1.71

Alector Financials Summary

As of 30-Sep-2024, Alector has a trailing 12-month revenue of $61.5M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (13,705) 122,780 49,474 949,122
Revenue 61,508 97,062 133,617 207,085
EBITDA (147,642) (116,331) (121,584) (28,014)
Net Income (158,409) (130,391) (133,310) (36,329)
Total Assets 516,023 621,827 787,648 814,658
Total Debt 34,639 38,918 43,327 47,601
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alector Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alector‘s full profile, request access.

Request a free trial

Alector Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for
Drug Discovery
South San Francisco, CA
241 As of 2024

New York, NY
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alector Competitors (72)

One of Alector’s 72 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cognition Therapeutics Formerly VC-backed New York, NY
Lexeo Therapeutics Formerly VC-backed New York, NY
PAQ Therapeutics Venture Capital-Backed Cambridge, MA
Orchard Therapeutics Formerly VC-backed London, United Kingdom
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
You’re viewing 5 of 72 competitors. Get the full list »

Alector Patents

Alector Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023225020-A1 Methods of use of anti-trem2 antibodies Pending 23-Feb-2022
US-20240329054-A1 Soluble cd33 as a biomarker for anti-cd33 efficacy Pending 08-Nov-2021
EP-4419558-A1 Anti-cd300lb antibodies and methods of use thereof Pending 19-Oct-2021
US-20240254227-A1 Anti-cd300lb antibodies and methods of use thereof Pending 19-Oct-2021
EP-4392448-A2 Pilra antibodies and methods of use thereof Pending 25-Aug-2021 C07K16/2803
To view Alector’s complete patent history, request access »

Alector Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alector Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alector‘s full profile, request access.

Request a free trial

Alector ESG

Risk Overview

Risk Rating

Updated February, 01, 2024

27.33 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,035

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view Alector’s complete esg history, request access »

Alector FAQs

  • When was Alector founded?

    Alector was founded in 2013.

  • Where is Alector headquartered?

    Alector is headquartered in South San Francisco, CA.

  • What is the size of Alector?

    Alector has 241 total employees.

  • What industry is Alector in?

    Alector’s primary industry is Drug Discovery.

  • Is Alector a private or public company?

    Alector is a Public company.

  • What is Alector’s stock symbol?

    The ticker symbol for Alector is ALEC.

  • What is the current stock price of Alector?

    As of 08-Nov-2024 the stock price of Alector is $5.75.

  • What is the current market cap of Alector?

    The current market capitalization of Alector is $563M.

  • What is Alector’s current revenue?

    The trailing twelve month revenue for Alector is $61.5M.

  • Who are Alector’s competitors?

    Cognition Therapeutics, Lexeo Therapeutics, PAQ Therapeutics, Orchard Therapeutics, and CRISPR Therapeutics are some of the 72 competitors of Alector.

  • What is Alector’s annual earnings per share (EPS)?

    Alector’s EPS for 12 months was -$1.71.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »